Azactam


Also found in: Dictionary, Medical.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for Azactam

an antibiotic (trade name Azactam) used against severe infections

References in periodicals archive ?
The overall resistances offered by the isolates against different antibiotics are as follows: 95% resistance offered to tetracycline, 94% to ampicillin, 92% to azactam, 88% to ceftriaxone, 85% to ciprofloxacin and augmentin, 78% to cefotaxime, 63% to ceftazidime, 60% to gentamicin and 49% to tobramicin.
Revenue for Azactam and Maxipime for the first quarter of 2010 was $25.
The decrease in revenue from the BioNeurology business was due to the cessation of revenue from Maxipime, Azactam and Prialt, offset by increased revenue from Tysabri.
The increases for the full-year and fourth quarter of 2010 were primarily due to growth in Tysabri and the launch of Ampyra, which more than offset the expected decline in revenue from Maxipime, Azactam, Skelaxin and Prialt.
5 million operating loss before the net gain on divestment of business and other net charges recorded by the BioNeurology business in the third quarter of 2009, and reflects the continued growth in Tysabri revenues offsetting the expected reduced revenues from Azactam and Prialt, in addition to a 16% reduction in combined SG&A and R&D expenses.
In assessing the first half performance, it is important to note that these results were achieved against a background where we have, as expected, seen reduced revenues from a number of products including Azactam and Prialt([R]) in the BioNeurology business and Skelaxin([R]) and Tricor([R]) in the Elan Drug Technologies (EDT) business, as well as an increased investment in development activities related particularly to Tysabri, ELND005 and the EDT business.
The increased gross margin principally reflects higher sales of Tysabri, which more than offset lower gross margins on Maxipime, Azactam and the EDT business.
The increase was primarily due to solid growth in Tysabri sales, which more than compensated for reduced sales of Azactam and Maxipime.
The increased gross margin was driven by the 30% increase in sales of Tysabri and the Fampridine-SR license fee, which more than offset the loss of gross margin as a result of reduced sales of Azactam and Maxipime.
The increased gross margin was driven by significantly higher sales of Tysabri, which more than offset the loss of gross margin as a result of reduced sales of Azactam, Maxipime and revenues from EDT.
For the full-year 2008, revenue from Azactam increased 12% to $96.
Although total revenue increased by 53%, selling, general and administrative (SG&A) expenses declined by 6%, reflecting reduced sales and marketing costs and amortization expense relating to Maxipime and Azactam, and the operating leverage associated with Tysabri.
Although revenue increased by 30%, selling, general and administrative (SG&A) expenses declined by 15%, reflecting reduced sales and marketing costs and amortization expense relating to Maxipime and Azactam, and the operating leverage associated with Tysabri.
This target was achieved and, as a result, SG&A costs related to Maxipime and Azactam were $24.